Skip to main content


Warwick joins university partnership to launch Midlands Innovation Commercialisation of Research Accelerator (MICRA)

The University of Warwick is part of a new connected system of technology transfer offices that has been launched to drive jobs and economic growth across the Midlands region, following a £5million award from Research England.

Mon 16 April 2018, 16:24

£8 million expansion of programme to commercialise research

An £8 million expansion of the Innovation to Commercialisation of University Research (ICURe) pilot programme will allow even more commercially-promising ideas to get to market more quickly. The funding will see the University of Warwick and Queen’s University Belfast join the programme, which is supported by Innovate UK, part of the new national funding body UK Research and Innovation.

Thu 12 April 2018, 14:38

Recycling Technologies announces £3.7m in new investment

Recycling Technologies, a company specialising in the chemical recycling of mixed plastic waste and based upon research originating at the University of Warwick, has announced that it has raised £3.7m in new investment including a major strategic £1m equity investment from global energy trader, InterChem.

Mon 19 March 2018, 08:42 | Tags: Warwick Ventures

Medherant expands team with appointment of Head of Development

Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development. This appointment marks a significant expansion of the Company’s management team to support the business as it moves into clinical development of its ibuprofen TEPI Patch®.

Fri 09 March 2018, 09:00

New business mentoring scheme to help early career researchers

Warwick Ventures is piloting a new mentoring scheme to match experienced business professionals with early career researchers to help coach the researchers and encourage them in viewing their ideas through a commercial lens.

Tue 16 January 2018, 09:03 | Tags: ICURe

VirionHealth Receives up to $4.2m from DARPA

VirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has won non-dilutive funding worth up to $4.2 million from the US Defense Advanced Research Projects Agency (DARPA).

Tue 09 January 2018, 10:47 | Tags: Warwick Ventures

Warwick spin-out Medherant completes £3.8 million funding round

Medherant, a spin-out company from the University of Warwick developing an innovative transdermal drug delivery patch technology, has raised £3.8 million in its latest funding round.

Wed 20 December 2017, 08:41 | Tags: Warwick Ventures, Chemistry

Spin-out Medherant wins Excellence in Science and Technology Award

Warwick spin-out Medherant Ltd has won the Excellence in Science and Technology Award at the Coventry Telegraph Business Awards 2017. The regional business award recognises the team’s rapid progress and innovation in the development of next-generation transdermal drug delivery patches. Read more about Medherant here.

Thu 23 November 2017, 14:29

Base4 Innovation Ltd. closes £5 million ($6.5 million) funding round

Founded in 2007 with support from Warwick Ventures and the University of Warwick, Base4 has just closed a £5 million funding round, the company's largest to date. The funds will be used to expand the current team and increase lab space, facilitating the continued fast-paced development and automation of its technology.

Wed 22 November 2017, 15:08 | Tags: Warwick Ventures, Life Sciences and Biotechnology

VirionHealth Raises Series A Funding from Abingworth

virionhealth_signing.jpgVirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has raised up to £13 million in Series A funding from Abingworth, the international investment group dedicated to life sciences.

VirionHealth is a University of Warwick spinout company, set up with the support of Warwick Ventures, in 2017. Dr Laura Lane, Business Development Manager at Warwick Ventures, worked closely with Professors Nigel Dimmock and Andrew Easton to build a commercial team and secure the largest single investment into a Warwick spinout.

Warwick Ventures also helped secure translational funding from the Wellcome Trust, maintained the patents and developed the business plan that led to the investment by Abingworth.

Thu 12 October 2017, 13:27 | Tags: Warwick Ventures, Life Sciences and Biotechnology

Older news